Neurovance Raises $3 Million Venture Equity
Wednesday, April 02, 2014 5:53:00 AM PDT | VentureDeal
Cambridge, Massachusetts -- Pharmaceutical technology company Neurovance (no website) has received $3 million in venture capital investment, according to an SEC regulatory filing.
Neurovance is a stealth stage company that is developing pharmaceutical preparations for the treatment of central nervous system disorders.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
Neurovance is still seeking $3.3 million in additional financing, according to the filing, in minimum investment sizes of $16,345.
Email Page | Print Page